REQUEST A DEMO
Total
USD $0.00
Search more companies

EuBiologics Co.,Ltd. (South Korea)

Main Activities: Biological Product (except Diagnostic) Manufacturing
Full name: EuBiologics Co.,Ltd. Profile Updated: June 19, 2025
Buy our report for this company USD 29.95 Most recent financial data: 2024 Available in: English Download a sample report

The Company is a Korea-based company principally engaged in manufacture and distribution of biopharmaceuticals. The Company also engaged in development of biopharmaceuticals and vaccine. The Company was established on March 10, 2010. The Company share was listed on the Korea Securities Dealers Automated Quotation System ( KOSDAQ ) on January 24, 2017.

Headquarters
8F, Seongdo Bldg., 207, Dosan-Daero, Gangnam-Gu
Seoul; Seoul;

Contact Details: Purchase the EuBiologics Co.,Ltd. report to view the information.

Website: http://www.eubiologics.com

Basic Information
Total Employees:
Purchase the EuBiologics Co.,Ltd. report to view the information.
Outstanding Shares:
Purchase the EuBiologics Co.,Ltd. report to view the information.
Registered Capital:
Purchase the EuBiologics Co.,Ltd. report to view the information.
Financial Auditors:
Purchase the EuBiologics Co.,Ltd. report to view the information.
Incorporation Date:
March 10, 2010
Key Executives
Purchase this report to view the information.
Chief Executive Officer
Ownership Details
Purchase this report to view the information.
9.9%
Purchase this report to view the information.
8.4%
Purchase this report to view the information.
6.3%
Subsidiaries
(주)벡스퍼트
Company Performance
Financial values in the chart are available after EuBiologics Co.,Ltd. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency KRW. Absolute financial data is included in the purchased report.
Net sales revenue
228.52%
Total operating revenue
230.85%
Operating profit (EBIT)
34151.37%
EBITDA
540.63%
Net Profit (Loss) for the Period
N/A
Total assets
46.63%
Total equity
45.03%
Operating Profit Margin (ROS)
33.71%
Net Profit Margin
N/A
Return on Equity (ROE)
N/A
Quick Ratio
0.94%
Cash Ratio
0.22%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?